MX2007004111A - Sal y formas cristalinas de la misma de un farmaco. - Google Patents

Sal y formas cristalinas de la misma de un farmaco.

Info

Publication number
MX2007004111A
MX2007004111A MX2007004111A MX2007004111A MX2007004111A MX 2007004111 A MX2007004111 A MX 2007004111A MX 2007004111 A MX2007004111 A MX 2007004111A MX 2007004111 A MX2007004111 A MX 2007004111A MX 2007004111 A MX2007004111 A MX 2007004111A
Authority
MX
Mexico
Prior art keywords
drug
salt
crystalline forms
inhibition
diseases
Prior art date
Application number
MX2007004111A
Other languages
English (en)
Inventor
David M Barnes
Geoff G Zhang
Michael F Bradley
Rodger Henry
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2007004111A publication Critical patent/MX2007004111A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/18—Polyhydroxylic acyclic alcohols
    • C07C31/26—Hexahydroxylic alcohols

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen una forma cristalina de un farmaco, formas para hacerla, composiciones que la contienen y metodos para el tratamiento de enfermedades e inhibicion de eventos fisiologicos adversos utilizandola.
MX2007004111A 2004-10-08 2005-10-07 Sal y formas cristalinas de la misma de un farmaco. MX2007004111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61733404P 2004-10-08 2004-10-08
PCT/US2005/036024 WO2006042034A2 (en) 2004-10-08 2005-10-07 Salt and crystalline forms thereof of a drug

Publications (1)

Publication Number Publication Date
MX2007004111A true MX2007004111A (es) 2007-06-14

Family

ID=36129950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004111A MX2007004111A (es) 2004-10-08 2005-10-07 Sal y formas cristalinas de la misma de un farmaco.

Country Status (13)

Country Link
US (8) US7728143B2 (es)
EP (3) EP3056492B1 (es)
CA (1) CA2582954C (es)
CY (1) CY1125048T1 (es)
DK (1) DK3056492T3 (es)
ES (1) ES2901955T3 (es)
HU (1) HUE056718T2 (es)
LT (1) LT3056492T (es)
MX (1) MX2007004111A (es)
PL (1) PL3056492T3 (es)
PT (1) PT3056492T (es)
SI (1) SI3056492T1 (es)
WO (1) WO2006042034A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
WO2006042034A2 (en) * 2004-10-08 2006-04-20 Abbott Laboratories Salt and crystalline forms thereof of a drug
PT1868581E (pt) * 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
EP2346855B1 (en) 2008-09-24 2017-04-05 Melinta Therapeutics, Inc. Process for making quinolone compounds
MY194407A (en) 2008-11-15 2022-11-30 Melinta Subsidiary Corp Antimicrobial Compositions
CN105189513A (zh) * 2013-03-08 2015-12-23 麦林塔医疗有限公司 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
EP2969004A4 (en) 2013-03-15 2016-09-21 Melinta Therapeutics Inc METHOD FOR THE TREATMENT OF INFECTIONS IN OVERWEIGHT AND ADIPOSIVE PATIENTS USING ANTIBIOTICS
TWI705814B (zh) 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
EA201791051A1 (ru) 2014-11-14 2018-01-31 Мелинта Терапьютикс, Инк. Способ лечения, профилактики или снижения риска возникновения кожной инфекции
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
CN106256824B (zh) * 2015-06-18 2020-10-27 重庆医药工业研究院有限责任公司 一种高纯度德拉沙星葡甲胺盐的制备方法
CN105017223B (zh) * 2015-07-08 2017-08-01 扬子江药业集团有限公司 德拉沙星葡甲胺晶型i及其制备方法
CN105017224A (zh) * 2015-07-10 2015-11-04 扬子江药业集团有限公司 一种德拉沙星葡甲胺晶型的制备方法
CN106916142A (zh) * 2015-12-25 2017-07-04 江苏奥赛康药业股份有限公司 一种制备高纯度德拉沙星的方法
CN111718331A (zh) * 2019-03-23 2020-09-29 南京海润医药有限公司 德拉沙星的杂质i和ii及产品精制方法
CN111718329A (zh) * 2019-03-23 2020-09-29 南京海润医药有限公司 一种德拉沙星杂质iv及产品精制方法
CN111718330A (zh) * 2019-03-23 2020-09-29 南京海润医药有限公司 一种德拉沙星杂质iii及产品精制方法
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
CN116514775A (zh) * 2022-01-20 2023-08-01 海南普利制药股份有限公司 一种徳拉沙星葡甲胺盐新晶型及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
US5578609A (en) * 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
ATE221533T1 (de) 1994-04-12 2002-08-15 Arakis Ltd Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten
EP0992501B1 (en) * 1995-09-22 2002-08-28 Wakunaga Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives as antibacterial agents
EP0945134A1 (de) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
AU2700301A (en) 2000-01-31 2001-08-14 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
JP4337283B2 (ja) 2001-07-11 2009-09-30 ソニー株式会社 光ピックアップ装置及び記録及び／又は再生装置
JP4290381B2 (ja) 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 ピリドンカルボン酸化合物含有エマルション
JP2004168772A (ja) 2002-11-06 2004-06-17 Takeda Chem Ind Ltd 受容体調節剤
WO2006042034A2 (en) * 2004-10-08 2006-04-20 Abbott Laboratories Salt and crystalline forms thereof of a drug

Also Published As

Publication number Publication date
US20140155380A1 (en) 2014-06-05
US8969569B2 (en) 2015-03-03
JP2008515910A (ja) 2008-05-15
US20150196547A1 (en) 2015-07-16
EP3056492A1 (en) 2016-08-17
US20180105510A1 (en) 2018-04-19
US9873681B2 (en) 2018-01-23
DK3056492T3 (da) 2021-12-13
US8648093B2 (en) 2014-02-11
US20100261703A1 (en) 2010-10-14
WO2006042034A8 (en) 2007-09-07
EP3056492B1 (en) 2021-09-22
PT3056492T (pt) 2021-12-27
WO2006042034A2 (en) 2006-04-20
JP5294633B2 (ja) 2013-09-18
CA2582954A1 (en) 2006-04-20
CA2582954C (en) 2014-07-29
SI3056492T1 (sl) 2022-03-31
ES2901955T3 (es) 2022-03-24
EP3957632A1 (en) 2022-02-23
CY1125048T1 (el) 2023-06-09
HUE056718T2 (hu) 2022-03-28
US10329276B2 (en) 2019-06-25
LT3056492T (lt) 2022-01-25
US20070043019A1 (en) 2007-02-22
EP1802607A2 (en) 2007-07-04
PL3056492T3 (pl) 2022-03-21
US7728143B2 (en) 2010-06-01
US8273892B2 (en) 2012-09-25
US20170073329A1 (en) 2017-03-16
US8252813B2 (en) 2012-08-28
WO2006042034A3 (en) 2006-06-22
US9539250B2 (en) 2017-01-10
US20130060040A1 (en) 2013-03-07
US20100286397A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
MX2007004111A (es) Sal y formas cristalinas de la misma de un farmaco.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
MX2020008616A (es) Rocio de fentanilo sublingual.
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
TW200626158A (en) Naphthaline derivatives
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
TW200639159A (en) Treatment of pain
SE0401342D0 (sv) Therapeutic compounds
MXPA05007181A (es) Cristales de la hormona de crecimiento humano y metodos para prepararlos.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
TW200626141A (en) Crystalline form of a drug
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
TW200505869A (en) Thiophenylaminoimidazolines
MX2010003771A (es) Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights